Gland Pharma Limited — Updates, 03-04-2025: Press Release

Gland Pharma Limited has received approval from the United States Food and Drug Administration (US FDA) for its Acetaminophen Injection, available in 10 mg/mL (500mg/50mL and 1000mg/100mL) bags. This product is bioequivalent to the reference listed drug from B. Braun Medical Inc. and is indicated for managing mild to moderate pain in patients aged two and older, as well as moderate to severe pain in conjunction with opioid analgesics.

The company plans to launch the product through its marketing partner soon, capitalizing on the significant market opportunity, with US sales recorded at approximately USD 55 million for the twelve months ending February 2025. Gland's long-standing reputation in the injectable pharmaceutical sector, operating in over 60 countries, positions it well for future growth. Investors should monitor the forthcoming product launch, as it presents a potential revenue boost and strengthens Gland's market presence.